Comcast Corporation (CMCSA) capitalization

Current snapshot

Market Cap
$103.84B
3.62B shares × $28.71 · as of last filing 2026-03-31
Net Worth
$88.27B
Stockholders' equity · 2026-03-31
Enterprise Value
$188.96B
Market cap + debt − cash
Net Debt
$85.11B
Debt $94.60B − Cash $9.49B

Annual history

One row per fiscal year (10-K). Market cap uses split-adjusted closing price on the fiscal-year-end date × shares outstanding.

Period End Market Cap
FY'25 2025-12-31 $110.86B
FY'24 2024-12-31 $146.67B
FY'23 2023-12-31 $181.89B
FY'22 2022-12-31 $154.92B
FY'21 2021-12-31 $234.24B
FY'20 2020-12-31 $242.30B
FY'19 2019-12-31 $207.31B
FY'17 2018-12-31 $157.99B
FY'17 2017-12-31 $191.68B
FY'16 2016-12-31 $336.62B
FY'15 2015-12-31 $284.13B
FY'14 2014-12-31 $151.99B
FY'13 2013-12-31 $138.50B
FY'12 2012-12-31 $101.51B
FY'11 2011-12-31 $65.87B
FY'10 2010-12-31 $61.96B
FY'09 2009-12-31 $48.64B
FY'09 2008-12-31 $49.83B
FY'09 2007-12-31

Quarterly history

One row per quarter (10-Q and Q4 from 10-K). Market cap uses split-adjusted closing price on the quarter-end date × shares outstanding.

Period End Market Cap
Q1'26 2026-03-31 $103.84B
Q4'25 2025-12-31 $110.86B
Q3'25 2025-09-30 $115.91B
Q2'25 2025-06-30 $133.02B
Q1'25 2025-03-31 $139.63B
Q4'24 2024-12-31 $146.67B
Q3'24 2024-09-30 $162.07B
Q2'24 2024-06-30 $153.51B
Q1'24 2024-03-31 $173.05B
Q4'23 2023-12-31 $181.89B
Q3'23 2023-09-30 $183.61B
Q2'23 2023-06-30 $173.80B
Q1'23 2023-03-31 $160.25B
Q4'22 2022-12-31 $154.92B
Q3'22 2022-09-30 $128.38B
Q2'22 2022-06-30 $175.87B
Q1'22 2022-03-31 $213.41B
Q4'21 2021-12-31 $234.24B
Q3'21 2021-09-30 $260.91B
Q2'21 2021-06-30 $266.45B
Q1'21 2021-03-31 $252.42B
Q4'20 2020-12-31 $242.30B
Q3'20 2020-09-30 $214.09B
Q2'20 2020-06-30 $179.58B
Q1'20 2020-03-31 $158.73B
Q4'19 2019-12-31 $207.31B
Q3'19 2019-09-30 $208.22B
Q2'19 2019-06-30 $194.78B
Q1'19 2019-03-31 $183.67B
Q4'17 2018-12-31 $157.99B
Q3'18 2018-09-30 $163.56B
Q2'18 2018-06-30 $152.34B
Q1'18 2018-03-31 $160.77B
Q4'17 2017-12-31 $191.68B
Q3'17 2017-09-30 $183.82B
Q2'17 2017-06-30 $187.17B
Q1'17 2017-03-31 $181.63B
Q4'16 2016-12-31 $336.62B
Q3'16 2016-09-30 $322.48B
Q2'16 2016-06-30 $318.84B
Q1'16 2016-03-31 $300.82B
Q4'15 2015-12-31 $284.13B
Q3'15 2015-09-30 $142.31B
Q2'15 2015-06-30 $152.21B
Q1'15 2015-03-31 $144.34B
Q4'14 2014-12-31 $151.99B
Q3'14 2014-09-30 $140.69B
Q2'14 2014-06-30 $141.07B
Q1'14 2014-03-31 $132.36B
Q4'13 2013-12-31 $138.50B
Q3'13 2013-09-30 $119.93B
Q2'13 2013-06-30 $111.31B
Q1'13 2013-03-31 $112.30B
Q4'12 2012-12-31 $101.51B
Q3'12 2012-09-30 $96.61B
Q1'12 2012-06-30 $86.86B
Q1'12 2012-03-31 $82.35B
Q4'11 2011-12-31 $65.87B
Q3'11 2011-09-30 $57.76B
Q2'11 2011-06-30 $70.67B
Q1'11 2011-03-31 $69.34B
Q4'10 2010-12-31 $61.96B
Q3'10 2010-09-30 $50.80B
Q2'10 2010-06-30 $49.02B
Q1'10 2010-03-31 $53.42B
Q4'09 2009-12-31 $34.78B
Q3'09 2009-09-30 $48.56B
Q2'09 2009-06-30 $41.80B
Q1'10 2009-03-31
Q4'09 2008-12-31 $49.83B
Q3'09 2008-09-30
Q2'09 2008-06-30

Methodology

Every figure on this page traces back to SEC EDGAR XBRL company-facts filings (CMCSA CIK 0001166691), tagged with the us-gaap and dei taxonomies. Filing-anchored figures are rendered server-side: the market cap and enterprise value tiles use the split-adjusted close on the latest reported period-end × shares outstanding, so they reconcile with the equity / debt / cash figures from that same filing. The two price-anchored tiles (market cap + enterprise value) re-anchor on the most recent daily close in the browser when JavaScript is enabled; shares outstanding and debt / cash stay filing-anchored, so the EV bridge still uses the latest statement of financial position. Historical share prices come from our total-returns daily history (split-adjusted); historical market caps are calibrated against today's share count to correct for SEC retroactive split restatements.

For the exact XBRL concepts and formulas, see the methodology reference for net worth, debt, cash, market cap, enterprise value, net debt, shares outstanding, and the historical-market-cap calibration.

Related tickers

AXON

Axon Enterprise, Inc.

HSTM

HEALTHSTREAM INC

RLMD

Relmada Therapeutics, Inc.